Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2005-05-10
2005-05-10
Wang, Shengjun (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C514S255060, C514S332000, C514S356000, C514S716000, C514S724000, C514S824000
Reexamination Certificate
active
06890958
ABSTRACT:
The present invention provides combinations of cardiovascular therapeutic compounds for the prophylaxis or treatment of cardiovascular disease including hypercholesterolemia, atherosclerosis, or hyperlipidemia. Combinations disclosed include a nicotinic acid derivative combined with a cholesteryl ester transfer protein (CETP) inhibitor.
REFERENCES:
patent: 3262850 (1966-07-01), Glynne
patent: 3287370 (1966-11-01), Mohrbacher
patent: 3389144 (1968-06-01), Mohrbacher
patent: 3520891 (1970-07-01), Mohrbacher
patent: 3674836 (1972-07-01), Creger
patent: 3692895 (1972-09-01), Nelson
patent: 3694448 (1972-09-01), Houlihan et al.
patent: 3714190 (1973-01-01), Boissier
patent: 3781328 (1973-12-01), Witte
patent: 3948973 (1976-04-01), Phillips
patent: 3962261 (1976-06-01), Zinnes
patent: 3972878 (1976-08-01), Schirmann
patent: 3983140 (1976-09-01), Endo
patent: 4002750 (1977-01-01), Ambrogi
patent: 4058552 (1977-11-01), Mieville
patent: 4185109 (1980-01-01), Rosen
patent: 4231938 (1980-11-01), Monaghan
patent: 4251526 (1981-02-01), McCall
patent: 4346227 (1982-08-01), Terahara
patent: 4410629 (1983-10-01), Terahara et al.
patent: 4444784 (1984-04-01), Hoffman
patent: 4448979 (1984-05-01), Terahara et al.
patent: 4559332 (1985-12-01), Grob
patent: 5075293 (1991-12-01), Reifschneider
patent: 5153184 (1992-10-01), Reifschneider
patent: 5158943 (1992-10-01), Sohda
patent: 5244887 (1993-09-01), Straub
patent: 5260316 (1993-11-01), Van Duzer
patent: 5334600 (1994-08-01), Van Duzer
patent: 5350761 (1994-09-01), Van Duzer
patent: 5354772 (1994-10-01), Kathawala
patent: 5430166 (1995-07-01), Kramer
patent: 5502045 (1996-03-01), Miettinen
patent: 5512558 (1996-04-01), Enhsen
patent: 5519001 (1996-05-01), Kushwaha
patent: 5602152 (1997-02-01), Berthelon
patent: 5610151 (1997-03-01), Glombik
patent: 5663165 (1997-09-01), Brieaddy
patent: 5703188 (1997-12-01), Mandeville
patent: 5705524 (1998-01-01), McGee
patent: 5723458 (1998-03-01), Brieaddy
patent: 5767115 (1998-06-01), Rosenblum
patent: 5929062 (1999-07-01), Haines
patent: 5994391 (1999-11-01), Lee
patent: 6020330 (2000-02-01), Enhsen
patent: 6034118 (2000-03-01), Bischofberger
patent: 6277831 (2001-08-01), Frick et al.
patent: A-3020992 (1992-12-01), None
patent: A-6194694 (1994-06-01), None
patent: A-6194894 (1994-06-01), None
patent: A-6194994 (1994-06-01), None
patent: 2025294 (1991-03-01), None
patent: 2078588 (1993-03-01), None
patent: 2085782 (1993-06-01), None
patent: 2085830 (1993-06-01), None
patent: 1211258 (1968-02-01), None
patent: 3 122 499 (1982-08-01), None
patent: 196 27 430 (1996-08-01), None
patent: 0 033 538 (1981-08-01), None
patent: 0 067 086 (1982-10-01), None
patent: 0 022 487 (1983-12-01), None
patent: 0 129 748 (1985-02-01), None
patent: 0 250 265 (1987-06-01), None
patent: 0 244 364 (1987-11-01), None
patent: 0 338 331 (1989-06-01), None
patent: 0 379 161 (1990-01-01), None
patent: 0 409 281 (1991-01-01), None
patent: 0 531 901 (1992-02-01), None
patent: 0 508 425 (1992-09-01), None
patent: 0 549 967 (1992-12-01), None
patent: 0 526 402 (1993-02-01), None
patent: 0 559 064 (1993-02-01), None
patent: 0 563 731 (1993-03-01), None
patent: 0 568 898 (1993-04-01), None
patent: 0 818 197 (1997-06-01), None
patent: 0 818 448 (1997-06-01), None
patent: 0 796 846 (1997-07-01), None
patent: 0 801 060 (1997-10-01), None
patent: 0 818 197 (1998-01-01), None
patent: 2 661 676 (1990-02-01), None
patent: 1 211 258 (1970-11-01), None
patent: 2 077 264 (1982-08-01), None
patent: 2 305 665 (1997-04-01), None
patent: 2 329 334 (1999-03-01), None
patent: 10-287662 (1998-10-01), None
patent: 8901477 (1989-02-01), None
patent: 9108205 (1991-06-01), None
patent: 9217467 (1992-10-01), None
patent: 9218115 (1992-10-01), None
patent: 9218462 (1992-10-01), None
patent: 9316055 (1993-08-01), None
patent: 9321146 (1993-10-01), None
patent: WO 9409774 (1994-05-01), None
patent: 9418183 (1994-08-01), None
patent: 9418184 (1994-08-01), None
patent: 9424087 (1994-10-01), None
patent: 9521843 (1995-08-01), None
patent: 9605188 (1996-02-01), None
patent: 9608484 (1996-03-01), None
patent: 9616051 (1996-05-01), None
patent: 9640255 (1996-12-01), None
patent: 9703953 (1997-02-01), None
patent: 9733882 (1997-09-01), None
patent: 9749387 (1997-12-01), None
patent: 9749736 (1997-12-01), None
patent: 9802432 (1998-01-01), None
patent: 9806405 (1998-02-01), None
patent: 9823593 (1998-06-01), None
patent: WO 9831225 (1998-07-01), None
patent: 9835937 (1998-08-01), None
patent: 9838182 (1998-09-01), None
patent: WO 9838182 (1998-09-01), None
patent: 9839299 (1998-09-01), None
patent: 9840375 (1998-09-01), None
patent: WO 9840375 (1998-09-01), None
patent: 9856757 (1998-12-01), None
patent: 9911259 (1999-03-01), None
patent: 9911260 (1999-03-01), None
patent: 9911263 (1999-03-01), None
patent: 9914174 (1999-03-01), None
patent: 9914204 (1999-03-01), None
patent: 9914215 (1999-03-01), None
patent: 9932478 (1999-07-01), None
patent: 9935135 (1999-07-01), None
patent: 9964409 (1999-12-01), None
patent: 0035889 (2000-06-01), None
patent: WO 00 61568 (2000-10-01), None
XP-000908990 “Choice of Lipid-Lowering Drugs,”The Medical Letter,vol. 38, No. 980, pp. 67-70 (1996).
Japanese Abstract XP 002137557: Banyu Pharm: “Treatment agent for hypercholesterolaemia, hyperlipaemia or arteriosclerosis—contains squalene epoxidase inhibitor and other anti-hperlipaemic agent,” Jul. 13, 1992.
European Search Report for EP Application No. 0 818 097 A1, mailed Jul. 14, 2003.
John R. Crouse, III, “New developments in the use of niacin for treatment of hyperlipidemia: new considerations in the use of an old drug,”Coronary Artery Disease,vol. 7, No. 4, pp. 321-326 (1996).
D. Roger Illingworth, “Management of Hyperlipidemia: Goals for the Prevention of Atherosclerosis,”Clin. And Investig. Med.,vol. 13, No. 4, pp. 211-218 (1990).
Gustav Schonfeld, “the effects of fibrates on lipoprotein and hemostatic coronary risk factors,”Atherosclerosis,vol. 111, pp. 171-174 (1994).
A. Barrett et al., “Total Synthesis and Stereochemical Assignment of the Quinquecyclopropane-Containing Cholesteryl Ester Transfer Protein Inhibitor U-106305”, J. Am Chem. Soc., 1996, 118, pp. 7863-7864.
P. Barter et al. “High Density Lipoproteins and Coronary Heart Disease”, Atherosclerosis, 121 1996, pp. 1-12.
A. Beckwith et al., “Iododediazoniation of Arenediazonium Salts Accompanied by Aryl Radical Ring Closure” J. Org. Chem. 1987, vol. 52, pp. 1992-1930.
D. Bilheimer et al., “Mevinolin and Colestipol Stimulate Receptor-Mediated Clearance of Low Density Lipoprotein From Plasma In Familial Hypercholesterolemia Heterzygotes”, Proc. Natl. Acad. Sci. USA, vol. 80, Jul. 1983, pp. 4124-4128.
C. Bisgaier et al., Cholesteryl Ester Transfer Protein Inhibition By PD 140195, Lipids, vol. 29, No. 12, 1994, pp. 811-818.
D. Blankenhorn et al., “Beneficial Effects of Combined Colestipol-Niacin Therapy On Coronary Atherosclerosis and Coronary Venous Bypass Grafts”, JAMA, Jun. 19, 1987, vol. 257, No. 23, pp. 3233-3240.
D. Blankenhorn et al., “Beneficial Effects of Colestipol-Niacin Therapy on the Common Carotid Artery” Circulation vol. 88, Jul. 1, 1993, pp. 20-28.
P. Bonin et al., “A Peptide Inhibitor Of Cholesteryl Ester Transfer Protein Identified By Screening a Bacteriophage Display Library”, Journal of Peptide Research, 51, 1998, pp. 216-225.
G. Brown, et al., “Regression of Coronary Artery Disease As A Result of Intensive Lipid-Lowering Therapy in Men With High Levels Of Apolipoprotein B”, The New England Journal of Medicine, vol. 323, Nov. 8, 1990, No. 19, pp. 1289-1339.
M. Brown et al., Induction of 3-hydroxy-3Methylglutaryl Coenzyme A Reductase Acitivity in Human Fibroblasts Incubated with Compactin (ML-236B), A Competitive Inhibitor of the Reductase, The Journal of Biological Chemistry, vol. 253, No. 4, Feb. 22, 1978, pp. 1121-1128.
S. Busch et al., “Cholesteryl Ester Analogs Inhibit Cholesteryl Ester But Not Triglyceride Transfer Cata
Glenn Kevin C.
Sikorski James A.
Benson Gregg C.
G.D. Searle LLC
Richardson Peter C.
Samuels Lisa A.
Wang Shengjun
LandOfFree
Combinations of cholesteryl ester transfer protein... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combinations of cholesteryl ester transfer protein..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combinations of cholesteryl ester transfer protein... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3454379